Influenza-specific T-cell receptor (TCR)

Influenza-specific T-cell receptors (TCRs) are specialized heterodimeric proteins expressed on the surface of T lymphocytes that mediate the recognition of influenza virus antigens. These receptors specifically bind to viral peptides, such as those derived from the conserved Matrix 1 (M1) or Nucleoprotein (NP), which are presented by Major Histocompatibility Complex (MHC) Class I or II molecules on infected cells (Testa et al., 2012; NIH, 2023). This interaction is a cornerstone of the adaptive immune response, triggering T-cell activation, proliferation, and the deployment of effector mechanisms like the release of perforin and granzymes to lyse infected cells (NIH, 2023). In addition to direct cytotoxicity, these TCRs stimulate the production of pro-inflammatory cytokines, such as interferon-gamma and tumor necrosis factor-alpha, which help orchestrate the broader antiviral response (NIH, 2023). In the context of disease, influenza-specific TCRs are vital for clearing active infections and providing cross-protective immunity against diverse viral strains (NIH, 2018). From a therapeutic perspective, these receptors are primary targets for the development of universal influenza vaccines and adoptive TCR-T cell therapies, which aim to enhance or engineer the cellular immune response (NIH, 2020). However, clinical application faces challenges including potential off-target cross-reactivity with self-peptides and the risk of immunopathology resulting from an overactive T-cell response (NIH, 2020; MDPI, 2023).

Other names

Flu-specific TCRInfluenza-reactive T-cell receptorInfluenza-specific T-lymphocyte receptor

Recognition of influenza-derived peptides presented on MHC molecules, leading to T-cell activation and targeted destruction of infected cells.